natural killer cell lymphoma pipeline insight

DelveInsight reports that over 100 key companies are actively engaged in developing more than 140 treatment therapies focused on Natural Killer (NK) Cell Therapies.

Natural Killer Cell Therapies Overview:

Natural Killer (NK) cells are a type of lymphocyte and a key part of the innate immune system, functioning as specialized immune defenders that target and destroy tumor cells and virus-infected cells. In individuals with cancer, NK cells often exhibit various functional impairments, including decreased cytotoxic activity, reduced expression of activating receptors, disrupted intracellular signaling, increased levels of inhibitory receptors, impaired proliferation, and reduced numbers in both the bloodstream and tumor tissues. Additionally, their ability to produce cytokines is often compromised.

NK cell therapy has shown the greatest promise in treating blood cancers such as leukemia. This form of immunotherapy can work by boosting the body’s natural NK cell response using stimulatory agents or by introducing external NK cells through methods like hematopoietic stem cell transplantation (HSCT) or adoptive cell transfer. A range of therapeutic approaches has been developed to maximize the effectiveness of NK cell-based treatments in cancer care.

Request for a detailed insights report on Natural Killer Cell Therapies pipeline insights

“Natural Killer Cell Therapies Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Natural Killer Cell Therapies Therapeutics Market.

Key Takeaways from the Natural Killer Cell Therapies Pipeline Report

• DelveInsight’s Natural Killer Cell Therapies pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer Cell Therapies treatment.

• In October 2024, ImmunityBio announced that the first patients had received doses in an initial trial evaluating the potential of its CAR-NK cell therapy targeting CD-19 for the treatment of non-Hodgkin’s lymphoma (NHL).

• In July 2024, the U.S. Food and Drug Administration (FDA) granted Nkarta approval to initiate a clinical trial for its cell therapy candidate, NKX019, in patients with ANCA-associated vasculitis (AAV) and other autoimmune disorders.

• In May 2024, KGen Biotech reported that its Safety Review Committee had approved the advancement of the company’s cryopreserved autologous, expanded, and enhanced SNK01 into Phase II clinical development.

• Key Natural Killer Cell Therapies companies such as ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating new drugs for Natural Killer Cell Therapies to improve the treatment landscape.

• Promising Natural Killer Cell Therapies pipeline therapies in various stages of development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others.

Natural Killer Cell Therapies Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Natural Killer Cell Therapies Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Natural Killer Cell Therapies treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Natural Killer Cell Therapies market.

Download our free sample page report on Natural Killer Cell Therapies pipeline insights

Natural Killer Cell Therapies Emerging Drugs

• Monalizumab: Innate Pharma

• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

• ALT 803: ImmunityBio

• ALECSAT: CytoVac

• PNK-007: Celularity

Natural Killer Cell Therapies Companies

Over 100 prominent companies are currently engaged in developing therapies centered on Natural Killer (NK) Cell treatments. Among these, Innate Pharma has a drug candidate that has progressed to the most advanced stage—Phase III clinical trials.

DelveInsight’s report covers around 140+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Natural Killer Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Natural Killer Cell Therapies Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Natural Killer Cell Therapies Therapies and Key Companies: Natural Killer Cell Therapies Clinical Trials and advancements

Natural Killer Cell Therapies Pipeline Therapeutic Assessment

• Natural Killer Cell Therapies Assessment by Product Type

• Natural Killer Cell Therapies By Stage

• Natural Killer Cell Therapies Assessment by Route of Administration

• Natural Killer Cell Therapies Assessment by Molecule Type

Download Natural Killer Cell Therapies Sample report to know in detail about the Natural Killer Cell Therapies treatment market @ Natural Killer Cell Therapies Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Natural Killer Cell Therapies Current Treatment Patterns

4. Natural Killer Cell Therapies – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Natural Killer Cell Therapies Late-Stage Products (Phase-III)

7. Natural Killer Cell Therapies Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Natural Killer Cell Therapies Discontinued Products

13. Natural Killer Cell Therapies Product Profiles

14. Natural Killer Cell Therapies Key Companies

15. Natural Killer Cell Therapies Key Products

16. Dormant and Discontinued Products

17. Natural Killer Cell Therapies Unmet Needs

18. Natural Killer Cell Therapies Future Perspectives

19. Natural Killer Cell Therapies Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Natural Killer Cell Therapies Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/